Avenue Therapeutics (ATXI) Downgraded by ValuEngine

ValuEngine cut shares of Avenue Therapeutics (NASDAQ:ATXI) from a buy rating to a hold rating in a research report released on Wednesday morning.

A number of other analysts have also recently weighed in on the company. Oppenheimer set a $10.00 price objective on Avenue Therapeutics and gave the stock a buy rating in a research report on Thursday, November 15th. HC Wainwright reissued a buy rating and issued a $11.00 price objective on shares of Avenue Therapeutics in a research report on Wednesday, August 15th.

Avenue Therapeutics stock opened at $5.28 on Wednesday. Avenue Therapeutics has a 1-year low of $2.08 and a 1-year high of $6.00.

In other Avenue Therapeutics news, Director Jeffrey Paley acquired 15,000 shares of the stock in a transaction dated Monday, December 10th. The stock was purchased at an average price of $5.24 per share, with a total value of $78,600.00. The acquisition was disclosed in a document filed with the SEC, which is available through this link. 5.00% of the stock is owned by company insiders.

About Avenue Therapeutics

Avenue Therapeutics, Inc, a specialty pharmaceutical company, acquires, licenses, develops, and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, which is in Phase III clinical trials to treat moderate to moderately severe post-operative pain.

See Also: Liquidity

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Avenue Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avenue Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit